Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > EPIX from US$1.6 to US$32 on P1 cancer data,18 months

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Feb 12, 2021 7:43am

148 Views

Post# 32549901

RE:RE:RE:RE:RE:RE:EPIX from US$1.6 to US$32 on P1 cancer data,18 months

don't get me wrong, I'm with you. It would be worth a whole lot more. You max your value based on all the facts. That's just an interim step on the way to developing the full pipeline value.

realitycheck4u wrote:

Wino115 wrote: I'll take $18 on THTX for Phase 1 data anyday.....

I am truly waiting until after they get acquired. I've been here far too long for $18